Impact of low molecular weight heparin (LMWH) on SARS-CoV2 Infection: HEPARIN SARS-CoV2 clinical trial.

Conclusions: No differences were found in the evolution of COVID between the two treatment groups for the profile of patients included in the trial. The increase in LMWH at an intermediate dose does not contribute benefits in a profile of patients with COVID who required hospitalization, but who had a favorable evolution in most of them. Financing: SEPAR 1128 and Neumosur Foundation. Enoxaparin 40mg/sc/day n(%) Enoxaparin 1 mg/Kg/day n(%) Mortality01(2)Oxigen therapy escalation21(37)17(31)Invasive mechanical ventilation1 (2)1 (2)Need for rescue medication17 (30)13 (24)Length of hospitalization; days median (IQR)7 (7)7 (7)Hemorrhages1 (2)2 (3.6)

Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Otero Candelera, R., Gonzalez-Vergara, D., Caparros, I., Garcia-Ortega, A., Rodriguez-Matute, C., Moises, J., Marin-Barrera, L., Rodriguez-Martorell, J. Tags: Respiratory infections and bronchiectasis Source Type: research